Liguria Responds to Multi-Drug Resistant Infection with Experimental Treatment
Genova, Italy – The Liguria region is demonstrating its commitment to public health by making an experimental drug, Sulbactam-durlobactam (Xacduro), available for a patient infected with carbapenem-resistant Acinetobacter baumannii (Crab). This action underscores the region’s ability to respond effectively to complex medical challenges,building on previous successes like providing support for patients injured in the Crans-Montana accident.
Understanding Acinetobacter baumannii and Crab
Acinetobacter baumannii is a bacterium that can cause severe infections,particularly in hospital settings. Crab, or carbapenem-resistant Acinetobacter baumannii, is a particularly hazardous strain because it is resistant to many commonly used antibiotics, including carbapenems, which are often considered a last resort. The increasing prevalence of antibiotic-resistant bacteria is a global health threat, necessitating the advancement and use of new treatments.
The Role of Sulbactam-durlobactam (Xacduro)
Sulbactam-durlobactam, marketed as Xacduro, is an innovative antibiotic combination not yet widely available in Italy.It is designed to combat Crab infections. the drug was requested by researchers at the Policlinico di Milano, specifically Professor Alessandra Bandera and Professor Giacomo Grasselli, for a patient under their care. The Policlinico San Martino in Liguria currently has a supply of the experimental drug and will provide it for the patient’s treatment.
Liguria’s Position as a Center for Antimicrobial Research
The Policlinico San Martino has a long-standing reputation as a national and international center for research into new antimicrobial drugs and the management of complex infections. Matteo Bassetti, Director of the Clinic of Infectious Diseases at the Policlinico San Martino, highlighted the center’s role in providing access to this experimental treatment.
Investment in Public Health and Collaboration
According to Liguria’s Regional Health Assessor, Massimo Nicolò, this situation highlights the importance of continued investment in public health, research, and inter-regional collaboration. “La Liguria, ancora una volta, si conferma all’altezza delle sfide più difficili,” Nicolò stated, emphasizing the region’s consistent ability to meet arduous challenges.
Key Takeaways
- liguria is providing access to the experimental antibiotic Sulbactam-durlobactam (Xacduro) to treat a patient with a carbapenem-resistant Acinetobacter baumannii infection.
- Crab is a dangerous, antibiotic-resistant bacterium posing a significant threat to public health.
- The policlinico San Martino is a leading center for antimicrobial research and the treatment of complex infections.
- Continued investment in public health and collaboration are crucial for addressing emerging health challenges.
Published: 2026/01/16 14:31:49
